RE:Even GlaxoSmithKline is curious about FLIM NADH/FAD ... ;-)So what ur saying Bbenny is that big pharma are finally showing interest in our field !! That's great and many,to ably 80% of pharma have no research going on in our field of science!! So, if one decided to get into our field of science because of all the exciting research in our field and wanted to get into our field reallly, reallly fast, like buying or partnering with a leading player in our field of science, might they see us as a good candidate to partner with??? And if Roger announced tomorrow that he was looking for a jv, these companies would obviously show interest and investigate and maybe three or four or 20 would put bids in so they too could be an instant player in this field???? Just saying, with all the things we have going for us, even an idiot can see pharma would be interested in instant credibility!!! Like, what other pharma has made their first three patients cancer free for over 90 days??? What other pharma has stopped the progression of the treated cancer in all their patients for over 180 days??? What other pharma did it with ONE TREATMENT, NO SIDE AFFECTS, WITH THE POSSIBILITY OF ACHIEVING AN IMMUNE AFFECT WITH HIGHER DOSE, OR MULTI TREATMENTS??? NAHHHH, ur right Yaz, NO pharma, when forced to bid or allow the it competitor to have this science, ur right, they would all say, TOO EARLY, NOTHING HERE ORANGE JUICE COULD GET THE SAME RESULTS, NO ONE WILL BID TO PE A PART OF THOSE RESULTS!!!!!!!!!!!!!!!! UR FUKKKKKKKKIN KIDDIN ME RIGHT!
bencro wrote: Interesting to see that big pharmas are interested in using the technique of Dr. Becker ((FLIM) for NADH/FAD) ...
Check this out:
Saturday 27 January 2018 Session 2: Pharmacodynamics Tomography: Drug Response and Therapeutic Effects Noninvasive monitoring of pharmacodynamics in the skin wound healing process using multimodal microscopy Paper 10475-8 Time: 12:00 PM - 12:20 PM Author(s): Jose D. Rico-Jimenez, Jang Hyuk Lee, Univ. of Illinois at Urbana-Champaign (United States); Aneesh Alex, GlaxoSmithKline (United States), Univ. of Illinois (United States); Eric J. Chaney, Ronit Barkalifa, Univ. of Illinois at Urbana-Champaign (United States); Eric Olson, David Adams, GlaxoSmithKline (United States); Marina Marjanovic, Univ. of Illinois at Urbana-Champaign (United States); Zane A. Arp, GlaxoSmithKline (United States); Stephen A. Boppart, Univ. of Illinois at Urbana-Champaign (United States) Hide Abstract
Monitoring angiogenesis, metabolic changes, and collagen deposition, is critical to elucidate the process of diabetic wound healing and to improve the development of therapeutic drugs. This study employs Optical Coherence Tomography Angiography (OCTA) for studying neovascularization,
Fluorescence Lifetime Imaging Microscopy (FLIM) for NADH/FAD assessment, Second Harmonic Generation (SHG) for analyzing collagen deposition, and Coherent anti-Stoke’s Raman Scattering (CARS) microscopy
for visualizing water/lipid distribution, together to non-invasively follow closure of a skin wound in healthy diabetic (db/db) mice treated with placebo and angiogenesis-promoting topical formulation (
GlaxoSmithKline). Here, the wound healing process is investigated to gain deeper understanding of the drug mechanism.
_______________________________
UPCOMING PRESENTATION
Wolfgang Becker, Cornelia Wetzker, Ales Benda
28 January 2018 • 11:00 - 11:20 AM | Part of SPIE BiOS _______________________________
Oxygen sensing PLIM together with FLIM of intrinsic cellular fluorophores for metabolic mapping Paper 10497-14
Time: 2:20 PM - 2:40 PM
Author(s):
Sviatlana Kalinina,
Patrick M. Schaefer, Jasmin Breymayer, Dominik Bisinger,
Univ. Ulm (Germany); Sabyasachi Chakrabortty, Max-Planck-Institut fr Polymerforschung (Germany);
Angelika Rueck, Univ. Ulm (Germany) Hide Abstract
Fluorescence lifetime imaging microscopy (FLIM) is used for monitoring intrinsic cellular fluorophores including the metabolic coenzyme NAD(P)H (nicotinamideadenine dinucleotide (phosphate)). The ratio between protein-bound and free NAD(P)H correlates with the balance between oxidative phosphorylation and glycolysis in the cells. The changes of the ratio reflects major cellular disorders. Our multichannel detection system was designed for simultaneous monitoring of NAD(P)H by FLIM and intracellular pO2 by PLIM (phosphorescence lifetime imaging microscopy) using oxygen sensitive probes. The FLIM/PLIM setup is based on two-photon microscopy and multi-dimensional time-correlated single-photon-counting (TCSPC). In addition, using one-photon excitation protoporphyrin IX FLIM imaging can be performed.
_____________________
Two-photon luminescence lifetime imaging microscopy (LIM) to follow up cell metabolism and oxygen consumption during theranostic applications (Invited Paper) Paper 10498-9 Time: 1:30 PM - 1:50 PM Author(s): Angelika C. Rueck, Jasmin Breymayer, Univ. Ulm (Germany); Lothar D. Lilge, Univ. Health Network (Canada), Univ. of Toronto (Canada); Arkadii Mandel, Theralase Technologies, Inc. (Canada); P. Schfer, Bjorn von Einem, Christine A. F. von Arnim, Sviatlana Kalinina, Univ. Ulm (Germany) Hide Abstract
A common property during tumor development is a switch between oxidative phosphorylation and glycolysis. The impact of this switch for theranostic applications could be significant. Interestingly altered metabolism could be correlated with a change in the fluorescence lifetimes of NAD(P)H and FAD. Besides, oxygen consumption has to be taken into account in order to understand treatment responses. For this, correlated imaging of phosphorescence and fluorescence lifetime parameters has been investigated and used to observe metabolic markers simultaneously with oxygen tension. Examples will be presented with respect to phosphorescent photosensitizers used in PDT of tumours and diagnosis of Alzheimers related disease.